ChromoGenics Interim Report January–June 2024
Key events during Q2 2024 During the first half of 2024, ChromoGenics continued its developmental journey with a strong focus on the customer and quality, continued to take measures to lower costs, and received an order for the manufacture of ConverLight® Dynamic from one of the company’s new European partners for a non-European customer. · ChromoGenics announced that it held an Extraordinary General Meeting, at which the Meeting resolved to approve the Board’s decision according to the above on directed issues of shares and therewith related proposals. The Extraordinary General